Cover Image
Market Research Report

Computer-Aided Drug Discovery Services Market, 2018-2030

Published by ROOTS ANALYSIS Product code 659682
Published Content info 315 Pages
Delivery time: 1-2 business days
Price
Back to Top
Computer-Aided Drug Discovery Services Market, 2018-2030
Published: June 27, 2018 Content info: 315 Pages
Description

The early stages of research related to drug discovery, including the identification of a relevant biological target and a viable lead compound, play a crucial role in the overall success of a drug candidate in preclinical and clinical studies. It is also worth noting that the process of drug discovery is extremely demanding, both in terms of capital requirements and time. Moreover, there is always a high risk of failure associated with R&D programs and, considering the increasing regulatory stringency, the approval of new drugs has become significantly more difficult.

Given the increase in complexity of the drug discovery process, the overall R&D spending in the pharmaceutical / biotechnology sector has grown from around USD 128 billion in 2008 to USD 158 billion in 2017. As a result, the industry is currently under tremendous pressure not only to meet the expectations of a growing patient population, but also to identify ways to mitigate the risks associated with novel drug discovery programs to avoid failure.

Over the years, various computational tools and services have emerged, enabling the selection, modeling, analysis and optimization of potential lead candidates. The predictive power of computer-aided drug discovery (CADD) has proven to be extremely advantageous, allowing researchers to bypass the random screening of billions of molecules across hundreds of biological targets. As a result, players offering novel in silico drug discovery services, such as CADD, have now become an integral part of the pharmaceutical industry. According to industry experts, almost 30% of the total cost and time invested in developing a new drug can be saved by utilizing such services. Owing to the significant cost benefits offered by such approaches, the adoption of CADD is anticipated to increase in the coming years. Furthermore, the growing number of drug discovery projects, coupled to their rapid progression through various stages of drug discovery, is expected to continue to create an increasing demand for computational services.

Synopsis:

The ‘Computer-Aided Drug Discovery Services Market, 2018-2030’ report features an extensive study on the current landscape and the likely future potential of the players providing CADD services for drug discovery. The study provides an in-depth analysis, highlighting the capabilities of a diverse set of companies that offer such services across different stages of drug discovery, such as target identification, target validation, hit generation, hit-to-lead and lead optimization. Amongst other elements, the report features:

  • An overview of the current market landscape, featuring a comprehensive list of over 120 players that offer CADD services, and detailed analysis based on a number of parameters, such as the location of headquarters, employee count, type of business model used (contract service providers, software / technology providers and consulting service providers), number of drug discovery step(s) for which the company offers CADD services (target identification, target validation, hit generation, hit-to-lead and lead optimization), type of molecule(s) (biologics and small molecules), type of clientele (pharmaceutical / biotechnology companies and academic / research institutes), CADD approach adopted (structure-based drug design, ligand-based drug design and fragment-based drug design) and type of CADD service(s) offered (docking, molecular modeling and virtual screening etc.). In addition, the report features a year-wise analysis of the number of players that have been established over the past three decades.
  • An analysis of the most active regions based on the presence of CADD service providers; the report contains a schematic world map representation indicating the geographical location of key hubs with respect to outsourcing activity within this domain.
  • A logo landscape of the industry players engaged in this domain, distributed on the basis of the location of their respective headquarters and company size (very small-sized (50 employees) and large (>200 employees)).
  • Elaborate profiles of established players that offer a comprehensive range of CADD services and have received funding in the past two decades. Each profile provides an overview of the company, its financial performance (if available), funding information (if available), information on its CADD specific service(s) portfolio, and a comprehensive future outlook. In addition, each profile features a peer group-based benchmark comparison matrix for the players based on several parameters, such as the number of CADD service(s) offered, number of drug discovery step(s), type of molecule(s), type of clientele and experience of the company.
  • Tabulated profiles of emerging players (mid-sized companies or start-ups, established after 2012), featuring details on company headquarters, year of establishment, number of employees, key executives, funding information (if available), CADD serviceportfolio, CADD technology(if any), key developments related to CADD (if any) and business strategy.
  • An analysis of investments made in this domain; these include seed financing, venture capital financing, debt financing, equity crowdfunding and grants / awards received by the companies that are operating in this area.
  • An elaborate valuation analysis of companies involved in providing CADD services to the pharmaceutical / biotechnology industry. For this purpose, we have focused only on companies that have received funding in the past two decades, and built a multi-variable dependent model to estimate the current valuation of the aforementioned players.
  • A detailed analysis of the cost saving potential in the drug discovery process that can be brought about by the adoption of CADD.
  • A discussion on the upcoming computational approaches (such as artificial intelligence and cloud computing) that are being adopted for drug discovery and are likely to impact early stage research over the coming years.

One of the key objectives of this report was to evaluate the current opportunity and the future potential of the CADD market over the coming decade. Based on several parameters, we have provided an informed estimate of the likely evolution of this market in the short to mid-term and long term, for the period 2018-2030. In addition, we have provided the likely distribution of the future opportunity based on [A] regional evolution of the market covering key geographies, such as North America (the US and Canada), Europe (Italy, Germany, France, Spain, the UK and rest of Europe), and Asia-Pacific (China, India and Japan), along with the rest of the world, [B] key step(s) of drug discovery (target identification, target validation, hit generation, hit-to-lead and lead optimization), [C] type of molecule(s) (biologics and small molecules), [D] type of sponsor (pharmaceutical / biotechnology companies and academic / research institutes) and [E] therapeutic areas. Considering the uncertainties associated with the growth of CADD market, and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

The opinions and insights presented in this study were influenced by inputs solicited via a comprehensive survey and discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with Edelmiro Moman (Scientific Consultant and Teacher, ProSciens), John L Kulp (Chief Executive Officerand Chief Technical Officer, Conifer Point Pharmaceuticals), Mark Whittaker(Senior Vice President, Evotec), and Sven Benson (Founder, candidum). All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Example Highlights:

  • 1. During our research, we identified over 120 players that are actively involved in providing a wide array of CADD services for drug discovery; lead optimization, hit-to-lead and lead generation are amongst the most popular drug discovery steps for which such services are offered. Around 15 companies offer end-to-end CADD services for drug discovery, starting from target identification to lead optimization. Examples of such one-stop-shops include (in alphabetical order)Allesh Biosciences Labs, CompChem Solutions, Evotec, Gfree Bio, GVK Biosciences, Quantitative Medicine, Sai Life Sciences, Shechter Computational Solutions and SilicsBio.
  • 2. The current market is characterized by the presence of several established, as well as emerging players. Of these, 23% are large companies (more than 200 employees), 15% are mid-sized companies (50-200 employees), while 62% are small-sized players (less than 50 employees). Examples of established players with more than 25 years of experience in the pharmaceutical sector include (in alphabetical order) AMRI, Charles River Laboratories, ChemDiv, Evotec, RTI International, Schrödingerand XRQTC. Some of the new players that have recently entered this domain include (in alphabetical order) ChemBio Discovery Solutions, Discover Drugs, Fractal Therapeutics, Micar Innovation, Nostrum Biodiscovery and NovaData Solutions.
  • 3. Around 80% of the CADD service providers are located in North America and Europe. It is also worth highlighting that there are several such players based in certain emerging regions within Asia Pacific, namely India and China. Examples of some of the large companies based in these locations include (in alphabetical order) ChemPartner, Excelra Knowledge Solutions, GVK Biosciences, Jubilant Biosys, Medicilon, Pharmaron, Sundia MediTech, Syngene, TCG Lifesciences, Viva Biotech and WuXi AppTec.
  • 4. CADD solutions / services have been shown to significantly reduce the cost and time spent in early stage drug discovery. The computation approach is estimated to save as much as 30% of this cost and also enables researchers to expedite the overall process, saving a significant amount of time. By 2030, we anticipate net annual cost savings of over USD 9 billion to be brought about by the adoption of CADD in the drug discovery process.
  • 5. Driven by the rising number of drugs in the discovery stage across various therapeutic areas, the market is expected to continue on its growth trajectory in the foreseen future. We expect the CADD market to grow at an annualized rate of ~12.4% between 2018 and 2030. In terms of therapeutic areas, oncological disorders (46%), neurological disorders (13%), immunological disorders (7%) and infectious diseases (6%) are expected to capture a significant fraction of the market by 2030.
  • 6. Hit and lead related services are expected to possess the largest market share (over 85%) by 2030, followed by target-based services (which include target identification and target validation). Although, the current market is largely driven (over 70%) by small molecules, large molecule drugs are expected to make a relatively larger contributions in the foreseen future; upcoming CADD technologies are likely to provide the necessary impetus to fuel this growth.
  • 7. In terms of geography, majority (~70%) of the market share is likely to be distributed between North America and Europe in 2030; other countries, such as China and Japan, are expected to grow at a relatively faster rate (~14%) in the coming decade.

Research Methodology:

The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market till 2030, the report also provides our independent view on various trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines:

Chapter 2 provides an executive summary of the key insights captured in our research. The summary offers a high-level view on the likely evolution of the CADD services market in the short to mid-term and long term.

Chapter 3 provides an introduction to the overall drug discovery process. It includes details on the time taken for a drug to traverse from the bench to the market, along with the historical evolution of CADD. It also provides an overview of CADD, its classification and applications in the drug discovery process. In addition, it provides an in-depth explanation of each step involved in the drug discovery process, along with details on associated CADD specific methods / technologies / approaches. It also highlights the benefits offered by CADD services in the drug discovery process. Further, the chapter features a discussion on the key challenges associated with conducting CADD research in-house, highlighting the evident shift towards outsourcing CADD related operations.

Chapter 4 provides a comprehensive review of the global landscape of the CADD services market. It includes information of over 120 players that are currently engaged in providing such services to the pharmaceutical / biotechnology industry. It features an in-depth market overview, including information on location of headquarters, employee count, type of business model used (contract service providers, software / technology providers and consulting service providers), number of drug discovery step(s) for which the company offers CADD services (target identification, target validation, hit generation, hit-to-lead and lead optimization), type of molecule(s) (biologics and small molecules), type of clientele (pharmaceutical / biotechnology companies and academic / research institutes), CADD approach adopted (structure-based drug design, ligand-based drug design and fragment-based drug design) and type of CADD service(s) offered (docking, molecular modeling and virtual screening etc.). The chapter also provides a list of CADD software / technologies, along with their developers, to represent the overall activity in this field. It also includes an indicative list of players offering CADD consulting services. In addition, the chapter also includes a logo landscape of the players engaged in this domain, distributed on the basis of the location of their respective headquarters and company size.

Chapter 5 features detailed profiles of established CADD service providers based in North America that have received funding in the past two decades. Each profile provides an overview of the company, its financial performance (if available), funding information (if available), information on its CADD specific service(s) portfolio, and a comprehensive future outlook. In addition, each profile features a peer group-based benchmark comparison matrix.The chapter also features tabulated profiles of emerging players based in North America (mid-sized companies or start-ups, established after 2012), featuring details on company headquarters, year of establishment, number of employees, key executives, funding information (if available), CADD serviceportfolio, CADD technology(if any), key developments related to CADD (if any) and business strategy.

Chapter 6 features detailed profiles of established CADD service providers based in Europe that have received funding in the past two decades. Each profile provides an overview of the company, its financial performance (if available), funding information (if available), information on its CADD specific service(s) portfolio, and a comprehensive future outlook. In addition, each profile features a peer group-based benchmark comparison matrix. The chapter also features tabulated profiles of emerging players based in Europe (mid-sized companies or start-ups, established after 2012), featuring details on company headquarters, year of establishment, number of employees, key executives, funding information (if available), CADD serviceportfolio, CADD technology(if any), key developments related to CADD (if any) and business strategy.

Chapter 7 features detailed profiles of established CADD service providers based in Asia-Pacific that have received funding in the past two decades. Each profile provides an overview of the company, its financial performance (if available), funding information (if available), information on its CADD specific service(s) portfolio, and a comprehensive future outlook. In addition, each profile features a peer group-based benchmark comparison matrix. The chapter also features tabulated profiles of emerging players based in Asia-Pacific (mid-sized companies or start-ups, established after 2012), featuring details on company headquarters, year of establishment, number of employees, key executives, funding information (if available), CADD serviceportfolio, CADD technology(if any), key developments related to CADD (if any) and business strategy.

Chapter 8 provides information on various investments and grants received by companies that are engaged in this domain. It includes a detailed analysis of the funding instances that have taken place in the period between 2010 and 2018, highlighting the growing interest of the venture capital community and other strategic investors in this domain.

Chapter 9 features a comprehensive valuation analysis of the companies that are offering CADD services for drug discovery. The chapter provides insights based on a multi-variable dependent valuation model, which is based on the year of establishment, employed workforce, funding received, and the depth of CADD service portfolio.

Chapter 10 presents insights generated from a detailed survey, wherein we invited over 200 stakeholders involved in outsourcing CADD services. The participants, who were primarily Directors / CXO level representatives of their respective companies, helped us develop a deeper understanding on the nature of their services and their associated commercial potential.

Chapter 11 presents a comprehensive analysis of the cost saving potential associated with using CADD in the drug discovery process.

Chapter 12 presents a comprehensive market forecast analysis, highlighting the future potential of the CADD industry till the year 2030. It features the likely distribution of the market based on [A] regional evolution of the market covering key geographies, such as North America (the US and Canada), Europe (Italy, Germany, France, Spain, the UK and rest of Europe), and Asia-Pacific (China, India and Japan), along with the rest of the world, [B] key step(s) of drug discovery (target identification, target validation, hit generation, hit-to-lead and lead optimization), [C] type of molecule(s) (biologics and small molecules), [D] type of sponsor (pharmaceutical / biotechnology companies and academic / research institutes) and [E] therapeutic areas.

Chapter 13 provides a brief overview of the upcoming computational technologies, which are being developed to deal with the innate complexities associated with the process of drug discovery and optimize the overall time spent on early stage research. We believe these novel technologies are likely to have a notable influence on the industry's evolution over the coming decade.

Chapter 14 is a collection of interview transcripts of discussions held with key stakeholders in this industry. In this chapter, we have presented the details of our conversations held with Edelmiro Moman (Scientific Consultant and Teacher, ProSciens), John L Kulp (Chief Executive Officer and Chief Technical Officer, Conifer Point Pharmaceuticals), Mark Whittaker(Senior Vice President, Evotec), Sven Benson (Founder, candidum).

Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 16 is an appendix, which provides the list of companies and organizations mentioned in the report.

Chapter 17 is an appendix, which features a detailed discussion of the various non-computational techniquesthat are being adopted for drug discovery and are likely to impact early stage research in the coming years.

Table of Contents
Product Code: RA100110

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Drug Discovery and Development Timeline
  • 3.3. An Overview of CADD
    • 3.3.1. Historical Evolution of CADD in the Drug Discovery Process
    • 3.3.2. Comparison of Traditional Drug Discovery Approaches and CADD
    • 3.3.3. Classification of CADD
  • 3.4. Applications of CADD in the Drug Discovery Process
    • 3.4.1. Target Identification
      • 3.4.1.1. Chemoinformatic Tools
      • 3.4.1.2. Network Based Drug Discovery
      • 3.4.1.3. Computational Platforms and Interaction Repository
    • 3.4.2. Target Validation
    • 3.4.3. Hit Generation
      • 3.4.3.1. High-Throughput Screening
      • 3.4.3.2. Fragment Based Screening
      • 3.4.3.3. Virtual Screening
    • 3.4.4. Hit-to-Lead
      • 3.4.4.1. Pharmacodynamics and Pharmacokinetics Modeling
      • 3.4.4.2. Other Approaches
    • 3.4.5. Lead Optimization
      • 3.4.5.1. Pharmacophore Modeling
      • 3.4.5.2. Docking
      • 3.4.5.3. SAR / QSAR
      • 3.4.5.4. Molecular Modeling
  • 3.5. Advantages of CADD in the Drug Discovery Process
  • 3.6. Challenges Associated with In-House CADD Operations
  • 3.7. Shift in Trend Towards Outsourcing of CADD Operations
  • 3.8. Concluding Remarks

4. MARKET LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. CADD Service Providers: List of Industry Players
    • 4.2.1. Distribution by Year of Establishment
    • 4.2.2. Distribution by Geographical Location
    • 4.2.3. Distribution by Company Size
    • 4.2.4. Distribution by Type of Business Model
    • 4.2.5. Distribution by Drug Discovery Steps
    • 4.2.6. Distribution by Type of Molecule
    • 4.2.7. Distribution by Type of Clientele
    • 4.2.8. Distribution by Type of CADD Approaches
    • 4.2.9. Distribution by Type of CADD Service Offering
    • 4.2.10. Distribution by Company Size and Location of Headquarters
  • 4.3. CADD: List of CADD Software / Technologies
  • 4.4. CADD: List of Consulting Service Providers

5. COMPANY PROFILES: NORTH AMERICA

  • 5.1. Chapter Overview
  • 5.2. Established Players
    • 5.2.1. Albany Molecular Research (AMRI)
      • 5.2.1.1. Company Snapshot
      • 5.2.1.2. Financial Information
      • 5.2.1.3. Funding and Investment Information
      • 5.2.1.4. CADD Service Portfolio
      • 5.2.1.5. Recent Developments and Future Outlook
      • 5.2.1.6. Company Benchmarking Output
    • 5.2.2. BioDuro
      • 5.2.2.1. Company Snapshot
      • 5.2.2.2. Funding and Investment Information
      • 5.2.2.3. CADD Service Portfolio
      • 5.2.2.4. Recent Developments and Future Outlook
      • 5.2.2.5. Company Benchmarking Output
    • 5.2.3. Charles River Laboratories
      • 5.2.3.1. Company Snapshot
      • 5.2.3.2. Financial Information
      • 5.2.3.3. Funding and Investment Information
      • 5.2.3.4. CADD Service Portfolio
      • 5.2.3.5. Recent Developments and Future Outlook
      • 5.2.3.6. Company Benchmarking Output
    • 5.2.4. Schrödinger
      • 5.2.4.1. Company Snapshot
      • 5.2.4.2. Funding and Investment Information
      • 5.2.4.3. CADD Service Portfolio
      • 5.2.4.4. Recent Developments and Future Outlook
      • 5.2.4.5. Company Benchmarking Output
  • 5.3. Emerging Players
    • 5.3.1. ChemBio Discovery Solutions
    • 5.3.2. Colorado Computational
    • 5.3.3. Conifer Point Pharmaceuticals
    • 5.3.4. Cyclica
    • 5.3.5. Fractal Therapeutics
    • 5.3.6. Insilico Medicine
    • 5.3.7. Shechter Computational Solutions
    • 5.3.8. Quantitative Medicine
    • 5.3.9. Zorilla Research

6. COMPANY PROFILES: EUROPE

  • 6.1. Chapter Overview
  • 6.2. Established Players
    • 6.2.1. BioNTech
      • 6.2.1.1. Company Snapshot
      • 6.2.1.2. Funding and Investment Information
      • 6.2.1.3. CADD Service Portfolio
      • 6.2.1.4. Recent Developments and Future Outlook
      • 6.2.1.5. Company Benchmarking Output
    • 6.2.2. Concept Life Sciences
      • 6.2.2.1. Company Snapshot
      • 6.2.2.2. Funding and Investment Information
      • 6.2.2.3. CADD Service Portfolio
      • 6.2.2.4. Recent Developments and Future Outlook
      • 6.2.2.5. Company Benchmarking Output
    • 6.2.3. Evotec
      • 6.2.3.1. Company Snapshot
      • 6.2.3.2. Financial Information
      • 6.2.3.3. Funding and Investment Information
      • 6.2.3.4. CADD Service Portfolio
      • 6.2.3.5. Recent Developments and Future Outlook
      • 6.2.3.6. Company Benchmarking Output
    • 6.2.4. Selvita
      • 6.2.4.1. Company Snapshot
      • 6.2.4.2. Financial Information
      • 6.2.4.3. Funding and Investment Information
      • 6.2.4.4. CADD Service Portfolio
      • 6.2.4.5. Recent Developments and Future Outlook
      • 6.2.4.6. Company Benchmarking Output
    • 6.2.5. Sygnature Discovery
      • 6.2.5.1. Company Snapshot
      • 6.2.5.2. Funding and Investment Information
      • 6.2.5.3. CADD Service Portfolio
      • 6.2.5.4. Recent Developments and Future Outlook
      • 6.2.5.5. Company Benchmarking Output
  • 6.3. Emerging Players
    • 6.3.1. BioAscent
    • 6.3.2. candidum
    • 6.3.3. Fidelta (A Subsidiary of Galapagos)
    • 6.3.4. Genomodel
    • 6.3.5. Micar Innovation
    • 6.3.6. Nostrum Biodiscovery
    • 6.3.7. NovaData Solutions
    • 6.3.8. Synsight

7. COMPANY PROFILES: ASIA-PACIFIC

  • 7.1. Chapter Overview
  • 7.2. Established Players
    • 7.2.1. GVK Biosciences
      • 7.2.1.1. Company Snapshot
      • 7.2.1.2. Financial Information
      • 7.2.1.3. Funding and Investment Information
      • 7.2.1.4. CADD Service Portfolio
      • 7.2.1.5. Recent Developments and Future Outlook
      • 7.2.1.6. Company Benchmarking Output
    • 7.2.2. Pharmaron
      • 7.2.2.1. Company Snapshot
      • 7.2.2.2. Funding and Investment Information
      • 7.2.2.3. CADD Service Portfolio
      • 7.2.2.4. Recent Developments and Future Outlook
      • 7.2.2.5. Company Benchmarking Output
    • 7.2.3. Sundia MediTech
      • 7.2.3.1. Company Snapshot
      • 7.2.3.2. Funding and Investment Information
      • 7.2.3.3. CADD Service Portfolio
      • 7.2.3.4. Recent Developments and Future Outlook
      • 7.2.3.5. Company Benchmarking Output
    • 7.2.4. WuXi AppTec
      • 7.2.4.1. Company Snapshot
      • 7.2.4.2. Financial Information
      • 7.2.4.3. Funding and Investment Information
      • 7.2.4.4. CADD Service Portfolio
      • 7.2.4.5. Recent Developments and Future Outlook
      • 7.2.4.6. Company Benchmarking Output
  • 7.3. Emerging Players
    • 7.3.1. Aaranya Biosciences
    • 7.3.2. Discover Drugs

8. FUNDING AND INVESTMENT ANALYSIS

  • 8.1. Chapter Overview
  • 8.2. Types of Funding
  • 8.3. CADD Service Providers: Funding and Investment Analysis
    • 8.3.1. Analysis by Cumulative Number of Funding Instances
    • 8.3.2. Analysis by Amount Invested
    • 8.3.3. Analysis by Type of Funding
    • 8.3.4. Analysis by Most Active Players
    • 8.3.5. Analysis by Most Active Investors
  • 8.4. Concluding Remarks

9. COMPANY VALUATION ANALYSIS

  • 9.1. Chapter Overview
  • 9.2. Company Valuation Analysis: Methodology
  • 9.3. Company Valuation Analysis: Categorization by Multiple Parameters
    • 9.3.1. Categorization by Employee Count
    • 9.3.2. Categorization by Google Hits
    • 9.3.3. Categorization by Weighted Average Score
    • 9.3.4. Company Valuation: Roots Analysis Proprietary Scores

10. SURVEY ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Overview of Respondents
  • 10.3. Drug Discovery Steps
  • 10.4. Type of Molecules
  • 10.5. CADD Service Portfolio
  • 10.6. Current Market Opportunity
  • 10.7. Likely Growth Rate
  • 10.8. Cost and Time Reduction using CADD

11. COST SAVING ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Key Assumptions
  • 11.3. Methodology
  • 11.4. Overall Cost Saving by using CADD, 2018-2030
  • 11.5. Concluding Remarks

12. MARKET FORECAST

  • 12.1. Chapter Overview
  • 12.2. Forecast Methodology and Key Assumptions
  • 12.3. Overall CADD Market, 2018-2030
  • 12.4. CADD Market, 2018-2030: Distribution by Regions
    • 12.4.1. CADD Market in North America, 2018-2030
      • 12.4.1.1. CADD Market in the US, 2018-2030
      • 12.4.1.2. CADD Market in Canada, 2018-2030
    • 12.4.2. CADD Market in Europe, 2018-2030
      • 12.4.2.1. CADD Market in Germany, 2018-2030
      • 12.4.2.2. CADD Market in France, 2018-2030
      • 12.4.2.3. CADD Market in the UK, 2018-2030
      • 12.4.2.4. CADD Market in Italy, 2018-2030
      • 12.4.2.5. CADD Market in Spain, 2018-2030
      • 12.4.2.6. CADD Market in Rest of Europe, 2018-2030
    • 12.4.3. CADD Market in Asia-Pacific and Rest of the World, 2018-2030
      • 12.4.3.1. CADD Market in Japan, 2018-2030
      • 12.4.3.2. CADD Market in China, 2018-2028
      • 12.4.3.3. CADD Market in India, 2018-2030
      • 12.4.3.4. CADD Market in Rest of the World, 2018-2030
  • 12.5. CADD Market, 2018-2030: Distribution by Drug Discovery Steps
    • 12.5.1. CADD Market for Target Identification, 2018-2030
    • 12.5.2. CADD Market for Target Validation, 2018-2030
    • 12.5.3. CADD Market for Hit Generation, 2018-2030
    • 12.5.4. CADD Market for Hit-to-Lead, 2018-2030
    • 12.5.5. CADD Market for Lead Optimization, 2018-2030
  • 12.6. CADD Market, 2018-2030: Distribution by Type of Molecule
    • 12.6.1. CADD Market for Small Molecules, 2018-2030
    • 12.6.2. CADD Market for Biologics, 2018-2030
  • 12.7. CADD Market, 2018-2030: Distribution by Therapeutic Areas
    • 12.7.1. CADD Market for Blood Disorders, 2018-2030
    • 12.7.2. CADD Market for Cardiovascular Disorders, 2018-2030
    • 12.7.3. CADD Market for Gastrointestinal and Digestive Disorders, 2018-2030
    • 12.7.4. CADD Market for Hormonal Disorders, 2018-2030
    • 12.7.5. CADD Market for Infectious Diseases, 2018-2030
    • 12.7.6. CADD Market for Immunological Disorders, 2018-2030
    • 12.7.7. CADD Market for Mental Disorders, 2018-2030
    • 12.7.8. CADD Market for Metabolic Disorders, 2018-2030
    • 12.7.9. CADD Market for Neurological Disorders, 2018-2030
    • 12.7.10. CADD Market for Oncological Disorders, 2018-2030
    • 12.7.11. CADD Market for Respiratory Disorders, 2018-2030
    • 12.7.12. CADD Market for Skin Disorders, 2018-2030
    • 12.7.13. CADD Market for Urogenital Disorders, 2018-2030
    • 12.7.14. CADD Market for Other Disorders, 2018-2030
    • 12.7.15. CADD Market, 2018-2030: Market Attractiveness Analysis by Therapeutic Areas
  • 12.8. CADD Market, 2018-2030: Distribution by Type of Sponsor
    • 12.8.1. CADD Market for Industry Players, 2018-2030
    • 12.8.2. CADD Market for Non-Industry Players, 2018-2030
  • 12.9. Concluding Remarks

13. CADD AND FUTURE TRENDS IN DRUG DISCOVERY

  • 13.1. Chapter Overview
  • 13.2. Owing to Potential Cost and Time Benefits, Outsourcing of Drug Discovery Operations is Expected to Increase in the Future
  • 13.3. Technological Advancements are Likely to Revolutionize the Current Drug Discovery Processes
    • 13.3.1. Integration of Artificial Intelligence in Drug Discovery is Expected to Improve the Overall Efficiency and Productivity
    • 13.3.2. Increased Adoption of Cloud Based Technology Platforms is Expected to Improve the Scalability and Flexibility of Drug Discovery Processes
  • 13.4. Concluding Remarks

14. EXECUTIVE INSIGHTS

  • 14.1. Chapter Overview
  • 14.2. ProSciens
    • 14.2.1. Company Snapshot
    • 14.2.2. Interview Transcript: Edelmiro Moman, Founder and Chief Executive Officer
  • 14.3. Conifer Point Pharmaceuticals
    • 14.3.1. Company Snapshot
    • 14.3.2. Interview Transcript: John L Kulp, Chief Executive Officer and Chief Technical Officer
  • 14.4. Evotec
    • 14.4.1. Company Snapshot
    • 14.4.2. Interview Transcript: Mark Whittaker, Senior Vice President, Drug Discovery
  • 14.5. candidum
    • 14.5.1. Company Snapshot
    • 14.5.2. Interview Transcript: Sven Benson, Founder

15. APPENDIX 1: TABULATED DATA

16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

17. APPENDIX 3: NON-COMPUTATIONAL METHODS FOR DRUG DISCOVERY

List of Figures

  • Figure 3.1: Drug Discovery and Development Timeline
  • Figure 3.2: Historical Evolution of Computational Drug Discovery Approaches
  • Figure 3.3: Steps Involved in Virtual Drug Discovery Process
  • Figure 3.4: Comparison of Traditional Drug Discovery Approaches and CADD
  • Figure 3.5: Classification of CADD Approaches
  • Figure 3.6: CADD Service Map for Drug Discovery Process
  • Figure 3.7: Advantages of using CADD in Drug Discovery Process
  • Figure 4.1: CADD Service Providers: Cumulative Number of Companies by Year of Establishment
  • Figure 4.2: CADD Service Providers: Distribution by Geographical Location
  • Figure 4.3: CADD Service Providers: Distribution by Countries
  • Figure 4.4: CADD Service Providers: Distribution by Company Size
  • Figure 4.5: CADD Service Providers: Distribution by Type of Business Model
  • Figure 4.6: CADD Service Providers: Distribution by Drug Discovery Steps
  • Figure 4.7: CADD Service Providers: Distribution by Type of Molecule
  • Figure 4.8: CADD Service Providers: Distribution by Type of Clientele
  • Figure 4.9: CADD Service Providers: Distribution by CADD Approaches
  • Figure 4.10: CADD Service Providers: Distribution by CADD Service Offering
  • Figure 4.11: CADD Service Providers Logo Landscape: Distribution by Company Size and Location of Headquarters
  • Figure 5.1: AMRI: Annual Revenues, 2012-Q1 2017 (USD Million)
  • Figure 5.2: AMRI: Contract Revenues by Business Segments, 2012-2016 (USD Million)
  • Figure 5.3: AMRI: CADD Service Portfolio
  • Figure 5.4: AMRI: Company Benchmarking Output
  • Figure 5.5: BioDuro: CADD Service Portfolio
  • Figure 5.6: BioDuro: Company Benchmarking Output
  • Figure 5.7: Charles River Laboratories: Business Segments
  • Figure 5.8: Charles River Laboratories: Revenues, 2013-Q1 2018 (USD Billion)
  • Figure 5.9: Charles River Laboratories: CADD Service Portfolio
  • Figure 5.10: Charles River Laboratories: Company Benchmarking Output
  • Figure 5.11: Schrödinger: CADD Service Portfolio
  • Figure 5.12: Schrödinger: CADD Software Suites and Packages
  • Figure 5.13: Schrödinger: Company Benchmarking Output
  • Figure 6.1: BioNTech: CADD Service Portfolio
  • Figure 6.2: BioNTech: Company Benchmarking Output
  • Figure 6.3: Concept Life Sciences: Company Benchmarking Output
  • Figure 6.4: Evotec: Revenues, 2013-Q1 2018 (EUR Million)
  • Figure 6.5: Evotec: Revenues by Business Divisions, 2017 (EUR Million)
  • Figure 6.6: Evotec: Drug Discovery Services
  • Figure 6.7: Evotec: CADD Service Portfolio
  • Figure 6.8: Evotec: Company Benchmarking Output
  • Figure 6.9: Selvita: Revenues, 2013-Q1 2018 (USD Million)
  • Figure 6.10: Selvita: CADD Service Portfolio
  • Figure 6.11: Selvita: Company Benchmarking Output
  • Figure 6.12: Sygnature Discovery: CADD Service Portfolio
  • Figure 6.13: Sygnature Discovery: Company Benchmarking Output
  • Figure 7.1: GVK Biosciences: Key Operating Segments
  • Figure 7.2: GVK Biosciences: CADD Service Portfolio
  • Figure 7.3: GVK Biosciences: Company Benchmarking Output
  • Figure 7.4: Pharmaron: CADD Service Portfolio
  • Figure 7.5: Pharmaron: Company Benchmarking Output
  • Figure 7.6: Sundia MediTech: CADD Service Portfolio
  • Figure 7.7: Sundia MediTech: Company Benchmarking Output
  • Figure 7.8: WuXi AppTec: Annual Revenues (USD Million)
  • Figure 7.9: WuXi AppTec: CADD Service Portfolio
  • Figure 7.10: WuXi AppTec: Company Benchmarking Output
  • Figure 8.1: CADD Service Providers: Cumulative Number of Funding Instances, 2010-2018
  • Figure 8.2: CADD Service Providers: Cumulative Amount Invested, 2010-2018 (USD Million)
  • Figure 8.3: CADD Service Providers: Distribution by Type of Funding, 2010-2018
  • Figure 8.4: CADD Service Providers: Distribution by Total Amount Invested and Type of Funding, 2010-2018 (USD Million)
  • Figure 8.5: CADD Service Providers: Most Active Players by Number of Instances, 2010-2018
  • Figure 8.6: CADD Service Providers: Most Active Players by Amount Invested, 2010-2018
  • Figure 8.7: CADD Service Providers: Most Active Investors by Number of Instances, 2010-2018
  • Figure 8.8: CADD Service Providers: Funding and Investment Summary
  • Figure 9.1: Company Valuation Analysis: A/Y Ratio, Input Dataset
  • Figure 9.2: Company Valuation Analysis: A/E Ratio, Input Dataset
  • Figure 9.3: Company Valuation Analysis: A/G Ratio, Input Dataset
  • Figure 9.4: Company Valuation Analysis: Categorization by Employee Count Score
  • Figure 9.5: Company Valuation Analysis: Categorization by Google Hits Score
  • Figure 9.6: Company Valuation Analysis: Categorization by Weighted Average Score
  • Figure 9.7: Company Valuation Analysis: High Value Players in CADD Industry
  • Figure 10.1: Survey Analysis: Distribution by Type of Company
  • Figure 10.2: Survey Analysis: Distribution by Location of Respondents
  • Figure 10.3: Survey Analysis: Distribution by Seniority Level of Respondents
  • Figure 10.4: Survey Analysis: Distribution by Drug Discovery Steps
  • Figure 10.5: Survey Analysis: Distribution by Type of Molecule
  • Figure 10.6: Survey Analysis: Distribution by CADD Service Portfolio
  • Figure 10.7: Survey Analysis: Distribution by Current Market Opportunity
  • Figure 10.8: Survey Analysis: Distribution by Likely Growth Rate
  • Figure 10.9: Survey Analysis: Distribution by Cost and Time Reduction using CADD
  • Figure 11.1: Approval Trend for Small Molecule and Large Molecule Drugs: Historical Data (2005-2017)
  • Figure 11.2: Overall Cost Saving by using CADD: Likely Scenarios
  • Figure 11.3: Overall Cost Saving by using CADD, 2018-2030 (USD Billion)
  • Figure 12.1: Overall CADD Market, 2018-2030: Base Scenario (USD Million)
  • Figure 12.2: CADD Market, 2018-2030: Distribution by Regions, Base Scenario (USD Million)
  • Figure 12.3: CADD Market, 2018-2030: North America, Base Scenario (USD Million)
  • Figure 12.4: CADD Market, 2018-2030: US, Base Scenario (USD Million)
  • Figure 12.5: CADD Market, 2018-2030: Canada, Base Scenario (USD Million)
  • Figure 12.6: CADD Market, 2018-2030: Europe, Base Scenario (USD Million)
  • Figure 12.7: CADD Market, 2018-2030: Germany, Base Scenario (USD Million)
  • Figure 12.8: CADD Market, 2018-2030: France, Base Scenario (USD Million)
  • Figure 12.9: CADD Market, 2018-2030: UK, Base Scenario (USD Million)
  • Figure 12.10: CADD Market, 2018-2030: Italy, Base Scenario (USD Million)
  • Figure 12.11: CADD Market, 2018-2030: Spain, Base Scenario (USD Million)
  • Figure 12.12: CADD Market, 2018-2030: Rest of Europe, Base Scenario (USD Million)
  • Figure 12.13: CADD Market, 2018-2030: Asia-Pacific and Rest of the World, Base Scenario (USD Million)
  • Figure 12.14: CADD Market, 2018-2030: Japan, Base Scenario (USD Million)
  • Figure 12.15: CADD Market, 2018-2030: China, Base Scenario (USD Million)
  • Figure 12.16: CADD Market, 2018-2030: India, Base Scenario (USD Million)
  • Figure 12.17: CADD Market, 2018-2030: Rest of the World, Base Scenario (USD Million)
  • Figure 12.18: CADD Market, 2018-2030: Distribution by Drug Discovery Steps, Base Scenario (USD Million)
  • Figure 12.19: CADD Market for Target Identification, 2018-2030: Base Scenario (USD Million)
  • Figure 12.20: CADD Market for Target Validation, 2018-2030: Base Scenario (USD Million)
  • Figure 12.21: CADD Market for Hit Generation, 2018-2030: Base Scenario (USD Million)
  • Figure 12.22: CADD Market for Hit-to-Lead, 2018-2030: Base Scenario (USD Million)
  • Figure 12.23: CADD Market for Lead Optimization, 2018-2030: Base Scenario (USD Million)
  • Figure 12.24: CADD Market, 2018-2030: Distribution by Type of Molecule, Base Scenario (USD Million)
  • Figure 12.25: CADD Market for Small Molecules, 2018-2030: Base Scenario (USD Million)
  • Figure 12.26: CADD Market for Biologics, 2018-2030: Base Scenario (USD Million)
  • Figure 12.27: CADD Market for Blood Disorders, 2018-2030: Base Scenario (USD Million)
  • Figure 12.28: CADD Market for Cardiovascular Disorders, 2018-2030: Base Scenario (USD Million)
  • Figure 12.29: CADD Market for Gastrointestinal and Digestive Disorders, 2018-2030: Base Scenario (USD Million)
  • Figure 12.30: CADD Market for Hormonal Disorders, 2018-2030: Base Scenario (USD Million)
  • Figure 12.31: CADD Market for Infectious Diseases, 2018-2030: Base Scenario (USD Million)
  • Figure 12.32: CADD Market for Immunological Disorders, 2018-2030: Base Scenario (USD Million)
  • Figure 12.33: CADD Market for Mental Disorders, 2018-2030: Base Scenario (USD Million)
  • Figure 12.34: CADD Market for Metabolic Disorders, 2018-2030: Base Scenario (USD Million)
  • Figure 12.35: CADD Market for Neurological Disorders, 2018-2030: Base Scenario (USD Million)
  • Figure 12.36: CADD Market for Oncological Disorders, 2018-2030: Base Scenario (USD Million)
  • Figure 12.37: CADD Market for Respiratory Disorders, 2018-2030: Base Scenario (USD Million)
  • Figure 12.38: CADD Market for Skin Disorders, 2018-2030: Base Scenario (USD Million)
  • Figure 12.39: CADD Market for Urogenital Disorders, 2018-2030: Base Scenario (USD Million)
  • Figure 12.40: CADD Market for Other Disorders, 2018-2030: Base Scenario (USD Million)
  • Figure 12.41: CADD Market, 2018-2030: Market Attractiveness by Therapeutic Areas, Base Scenario (USD Million)
  • Figure 12.42: CADD Market, 2018-2030: Distribution by Type of Sponsors, Base Scenario (USD Million)
  • Figure 12.43: CADD Market for Industry Players, 2018-2030: Base Scenario (USD Million)
  • Figure 12.44: CADD Market for Non-Industry Players, 2018-2030: Base Scenario (USD Million)
  • Figure 12.45: Overall CADD Market: Comparative Evolution Scenarios, 2018, 2024 and 2030 (USD Million)
  • Figure 13.1: Upcoming Trends in Drug Discovery: Future Growth Opportunities

List of Tables

  • Table 4.1: CADD Service Providers: List of Industry Players
  • Table 4.2: CADD Service Providers: Information on Drug Discovery Steps
  • Table 4.3: CADD Service Providers: Information on Type of Molecule
  • Table 4.4: CADD Service Providers: Information on Type of Clientele
  • Table 4.5: CADD Service Providers: Information on CADD Approaches
  • Table 4.6: CADD Service Providers: Information on CADD Service Offering
  • Table 4.7: CADD: List of CADD Software / Technologies
  • Table 4.8: CADD: List of Consulting Service Providers
  • Table 5.1: CADD Service Providers in North America: List of Companies Profiled
  • Table 5.2: AMRI: Key Highlights
  • Table 5.3: AMRI: List of Funding Instances and Investors
  • Table 5.4: AMRI: Future Outlook
  • Table 5.5: BioDuro: Key Highlights
  • Table 5.6: BioDuro: List of Funding Instances and Investors
  • Table 5.7: BioDuro: Future Outlook
  • Table 5.8: Charles River Laboratories: Key Highlights
  • Table 5.9: Charles River Laboratories: List of Funding Instances and Investors
  • Table 5.10: Charles River Laboratories: Future Outlook
  • Table 5.11: Schrödinger: Key Highlights
  • Table 5.12: Schrödinger: List of Funding Instances and Investors
  • Table 5.13: Schrödinger: Future Outlook
  • Table 5.14: Company Profile: ChemBio Discovery Solutions
  • Table 5.15: Company Profile: Colorado Computational
  • Table 5.16: Company Profile: Conifer Point Pharmaceuticals
  • Table 5.17: Company Profile: Cyclica
  • Table 5.18: Company Profile: Fractal Therapeutics
  • Table 5.19: Company Profile: Insilico Medicine
  • Table 5.20: Company Profile: Shechter Computational Solutions
  • Table 5.21: Company Profile: Quantitative Medicine
  • Table 5.22: Company Profile: Zorilla Research
  • Table 6.1: CADD Service Providers in Europe: List of Companies Profiled
  • Table 6.2: BioNTech: Key Highlights
  • Table 6.3: BioNTech: List of Funding Instances and Investors
  • Table 6.4: BioNTech: Future Outlook
  • Table 6.5: Concept Life Sciences: Key Highlights
  • Table 6.6: Spectris: List of Funding Instances and Investors
  • Table 6.7: Concept Life Sciences: Future Outlook
  • Table 6.8: Evotec: Key Highlights
  • Table 6.9: Evotec: List of Funding Instances and Investors
  • Table 6.10: Evotec: Future Outlook
  • Table 6.11: Selvita: Key Highlights
  • Table 6.12: Selvita: List of Funding Instances and Investors
  • Table 6.13: Selvita: Future Outlook
  • Table 6.14: Sygnature Discovery: Key Highlights
  • Table 6.15: Sygnature Discovery: List of Funding Instances and Investors
  • Table 6.16: Sygnature Discovery: Future Outlook
  • Table 6.17: Company Profile: BioAscent
  • Table 6.18: Company Profile: candidum
  • Table 6.19: Company Profile: Fidelta
  • Table 6.20: Company Profile: Genomodel
  • Table 6.21: Company Profile: Micar Innovation
  • Table 6.22: Company Profile: Nostrum Biodiscovery
  • Table 6.23: Company Profile: NovaData Solutions
  • Table 6.24: Company Profile: Synsight
  • Table 7.1: CADD Service Providers in Asia-Pacific: List of Companies Profiled
  • Table 7.2: GVK Biosciences: Key Highlights
  • Table 7.3: GVK Biosciences: List of Funding Instances and Investors
  • Table 7.4: GVK Biosciences: Future Outlook
  • Table 7.5: Pharmaron: Key Highlights
  • Table 7.6: Pharmaron: List of Funding Instances and Investors
  • Table 7.7: Pharmaron: Future Outlook
  • Table 7.8: Sundia MediTech: Key Highlights
  • Table 7.9: Sundia MediTech: List of Funding Instances and Investors
  • Table 7.10: Sundia MediTech: Future Outlook
  • Table 7.11: WuXi AppTec: Key Highlights
  • Table 7.12: WuXi AppTec: List of Funding Instances and Investors
  • Table 7.13: WuXi AppTec: Future Outlook
  • Table 7.14: Company Profile: Aaranya Biosciences
  • Table 7.15: Company Profile: Discover Drugs
  • Table 8.1: CADD Service Providers: Funding and Investments, 1999-2018
  • Table 8.2: CADD Service Providers: Summary of Investments
  • Table 9.1: Company Valuation Analysis: Sample Dataset
  • Table 9.2: Company Valuation Analysis: Weighted Average Evaluation
  • Table 9.3: Company Valuation Analysis: Estimated Valuation
  • Table 10.1: Survey Response: Overview of the Participating Companies
  • Table 10.2: Survey Response: Overview of Respondents
  • Table 10.3: Survey Response: Drug Discovery Steps
  • Table 10.4: Survey Response: Type of Molecules
  • Table 10.5: Survey Response: CADD Service Portfolio
  • Table 10.6: Survey Response: Current Market Opportunity
  • Table 10.7: Survey Response: Likely Growth Rate
  • Table 10.8: Survey Response: Cost and Time Reduction using CADD
  • Table 11.1: Likely Cost Reduction using CADD: Data from Survey Responses
  • Table 11.2: Drug Discovery Steps: Key Parameters
  • Table 13.1: Companies Offering Artificial Intelligence and CADD Services
  • Table 13.2: Companies Offering Cloud Computing Platforms and CADD Services
  • Table 14.1: ProSciens: Key Highlights
  • Table 15.1: CADD Service Providers: Cumulative Number of Companies by Year of Establishment
  • Table 15.2: CADD Service Providers: Distribution by Geographical Location
  • Table 15.3: CADD Service Providers: Distribution by Company Size
  • Table 15.4: CADD Service Providers: Distribution by Type of Business Model
  • Table 15.5: CADD Service Providers: Distribution by Drug Discovery Steps
  • Table 15.6: CADD Service Providers: Distribution by Type of Molecule
  • Table 15.7: CADD Service Providers: Distribution by Type of Clientele
  • Table 15.8: CADD Service Providers: Distribution by CADD Approaches
  • Table 15.9: CADD Service Providers: Distribution by CADD Service Offering
  • Table 15.10: AMRI: Annual Revenues, 2012-Q1 2017 (USD Million)
  • Table 15.11: AMRI: Contract Revenues by Business Segments, 2012-2016 (USD Million)
  • Table 15.12: Charles River Laboratories: Revenues, 2013-Q1 2018 (USD Billion)
  • Table 15.13: Evotec: Revenues, 2013-Q1 2018 (EUR Million)
  • Table 15.14: Evotec: Revenues by Business Divisions, 2017 (EUR Million)
  • Table 15.15: Selvita: Revenues, 2013-Q1 2018 (USD Million)
  • Table 15.16: WuXi AppTec: Annual Revenues (USD Million)
  • Table 15.17: CADD Service Providers: Cumulative Number of Funding Instances, 2010-2018
  • Table 15.18: CADD Service Providers: Cumulative Amount Invested, 2010-2018 (USD Million)
  • Table 15.19: CADD Service Providers: Distribution by Type of Funding, 2010-2018 (USD Million)
  • Table 15.20: CADD Service Providers: Distribution by Total Amount Invested and Type of Funding, 2010-2018 (USD Million)
  • Table 15.21: CADD Service Providers: Most Active Players by Number of Instances, 2010-2018
  • Table 15.22: CADD Service Providers: Most Active Players by Amount Invested, 2010-2018
  • Table 15.23: CADD Service Providers: Most Active Investors by Number of Instances, 2010-2018
  • Table 15.24: Company Valuation Analysis: A/Y Ratio, Input Dataset
  • Table 15.25: Company Valuation Analysis: A/E Ratio, Input Dataset
  • Table 15.26: Company Valuation Analysis: A/G Ratio, Input Dataset
  • Table 15.27: Survey Analysis: Distribution by Type of Company
  • Table 15.28: Survey Analysis: Distribution by Location of Respondents
  • Table 15.29: Survey Analysis: Distribution by Seniority Level of Respondents
  • Table 15.30: Survey Analysis: Distribution by Drug Discovery Steps
  • Table 15.31: Survey Analysis: Distribution by Type of Molecule
  • Table 15.32: Survey Analysis: Distribution by CADD Service Portfolio
  • Table 15.33: Survey Analysis: Distribution by Current Market Opportunity
  • Table 15.34: Survey Analysis: Distribution by Likely Growth Rate
  • Table 15.35: Survey Analysis: Distribution by Cost and Time Reduction using CADD
  • Table 15.36: Approved Small Molecules and Large Molecules: Historical Trend (2005-2017)
  • Table 15.37: Overall Cost Saving by using CADD, 2018-2030 (USD Billion)
  • Table 15.38: Overall CADD Market, 2018-2030: Conservative Scenario (USD Million)
  • Table 15.39: Overall CADD Market, 2018-2030: Base Scenario (USD Million)
  • Table 15.40: Overall CADD Market, 2018-2030: Optimistic Scenario (USD Million)
  • Table 15.41: CADD Market, 2018-2030: Distribution by Regions, Conservative Scenario (USD Million)
  • Table 15.42: CADD Market, 2018-2030: Distribution by Regions, Base Scenario (USD Million)
  • Table 15.43: CADD Market, 2018-2030: Distribution by Regions, Optimistic Scenario (USD Million)
  • Table 15.44: CADD Market, 2018-2030: North America, Conservative Scenario (USD Million)
  • Table 15.45: CADD Market, 2018-2030: North America, Base Scenario (USD Million)
  • Table 15.46: CADD Market, 2018-2030: North America, Optimistic Scenario (USD Million)
  • Table 15.47: CADD Market, 2018-2030: Europe, Conservative Scenario (USD Million)
  • Table 15.48: CADD Market, 2018-2030: Europe, Base Scenario (USD Million)
  • Table 15.49: CADD Market, 2018-2030: Europe, Optimistic Scenario (USD Million)
  • Table 15.50: CADD Market, 2018-2030: Asia-Pacific and Rest of the World, Conservative Scenario (USD Million)
  • Table 15.51: CADD Market, 2018-2030: Asia-Pacific and Rest of the World, Base Scenario (USD Million)
  • Table 15.52: CADD Market, 2018-2030: Asia-Pacific and Rest of the World, Optimistic Scenario (USD Million)
  • Table 15.53: CADD Market, 2018-2030: Distribution by Drug Discovery Steps, Conservative Scenario (USD Million)
  • Table 15.54: CADD Market, 2018-2030: Distribution by Drug Discovery Steps, Base Scenario (USD Million)
  • Table 15.55: CADD Market, 2018-2030: Distribution by Drug Discovery Steps, Optimistic Scenario (USD Million)
  • Table 15.56: CADD Market, 2018-2030: Distribution by Type of Molecule, Conservative Scenario (USD Million)
  • Table 15.57: CADD Market, 2018-2030: Distribution by Type of Molecule, Base Scenario (USD Million)
  • Table 15.58: CADD Market, 2018-2030: Distribution by Type of Molecule, Optimistic Scenario (USD Million)
  • Table 15.59: CADD Market, 2018-2030: Distribution by Therapeutic Areas, Conservative Scenario (USD Million)
  • Table 15.60: CADD Market, 2018-2030: Distribution by Therapeutic Areas, Base Scenario (USD Million)
  • Table 15.61: CADD Market, 2018-2030: Distribution by Therapeutic Areas, Optimistic Scenario (USD Million)
  • Table 15.62: CADD Market, 2018-2030: Market Attractiveness Analysis by Therapeutic Areas (USD Million)
  • Table 15.63: CADD Market, 2018-2030: Distribution by Type of Sponsors, Conservative Scenario (USD Million)
  • Table 15.64: CADD Market, 2018-2030: Distribution by Type of Sponsors, Base Scenario (USD Million)
  • Table 15.65: CADD Market, 2018-2030: Distribution by Type of Sponsors, Optimistic Scenario (USD Million)
  • Table 15.66: Overall CADD Market: Comparative Evolution Scenarios, 2018, 2024 and 2030 (USD Million)

Listed Companies

The following companies and organizations have been mentioned in the report:

  • 1. Aaranya Biosciences
  • 2. Agilux Laboratories
  • 3. Aisling Capital
  • 4. A-Level Capital
  • 5. Allesh Biosciences Labs
  • 6. Almi Invest
  • 7. AMRI
  • 8. Andy Jennings Consulting
  • 9. APEIRON Biologics
  • 10. Aprecia Pharmaceuticals
  • 11. Aptuit
  • 12. Aquila BioMedical
  • 13. Aragen Bioscience
  • 14. Aris Pharmaceuticals
  • 15. Asahi Kasei Pharma
  • 16. Asclepia MedChem Solutions
  • 17. AstraZeneca
  • 18. ATHOS Service
  • 19. Atlas Ventures
  • 20. Aurora Fine Chemicals
  • 21. Avistron Chemistry Services
  • 22. Banco Santander
  • 23. Bayer
  • 24. BenevolentAI
  • 25. BIANA
  • 26. Bienta
  • 27. BioAscent
  • 28. BioDiscovery Group
  • 29. BioDuro
  • 30. BioGenerator
  • 31. Biognos
  • 32. Bionomics
  • 33. BioNTech
  • 34. BioSolveIT
  • 35. Biotechnology Value Fund
  • 36. Biovista
  • 37. Blue Stream Laboratories
  • 38. BOC Sciences
  • 39. Brains On-Line
  • 40. Broad Institute
  • 41. CAChe Research
  • 42. candidum
  • 43. Carna Biosciences
  • 44. Carrick Therapeutics
  • 45. Cascade Investment
  • 46. Center for the Development of Industrial Technology
  • 47. Celgene
  • 48. Celsis
  • 49. Charles River Laboratories
  • 50. ChemAxon
  • 51. ChemBio Discovery Solutions
  • 52. ChemDiv
  • 53. ChemEnvision
  • 54. Chemical Computing Group
  • 55. ChemModeling
  • 56. ChemoGenics BioPharma
  • 57. Chemotargets
  • 58. ChemPartner
  • 59. China Canada Angels Alliance
  • 60. ChrysCapital
  • 61. CITIC M&A Fund
  • 62. Clearlake Capital Group
  • 63. Cloud Pharmaceuticals
  • 64. CloudScientific
  • 65. Colorado Computational
  • 66. CompChem Solutions
  • 67. Concept Life Science
  • 68. Confluence Discovery Technologies
  • 69. Conifer Point Pharmaceuticals
  • 70. Creative Biolabs
  • 71. Creative Biostructure
  • 72. Crelux
  • 73. Cresset
  • 74. Crowdcube
  • 75. CXR Biosciences
  • 76. Cyclica
  • 77. Cyprotex
  • 78. Cystic Fibrosis Foundation
  • 79. DCM Ventures
  • 80. Deep Knowledge Ventures
  • 81. Discover Drugs
  • 82. DIVERCHIM
  • 83. Eagle Pharmaceuticals
  • 84. Edelris
  • 85. Eli Lilly
  • 86. EligoChem
  • 87. Enamine Biology Services
  • 88. Entelos
  • 89. Epic Capital Management
  • 90. Equinox Pharma
  • 91. European Investment Fund
  • 92. Euticals
  • 93. Evotec
  • 94. Excelra Knowledge Solutions
  • 95. Exscientia
  • 96. Fidelity Management & Research Company
  • 97. Fidelta
  • 98. Formex
  • 99. Fractal Therapeutics
  • 100. Galapagos
  • 101. Genedata
  • 102. Genentech
  • 103. Genmab
  • 104. Genomodel
  • 105. Gfree Bio
  • 106. GL Capital
  • 107. GLSynthesis
  • 108. Government of Singapore Investment
  • 109. Greenpharma
  • 110. GreenSky Capital
  • 111. GTCR
  • 112. GVK Biosciences
  • 113. H3 Biomedicine
  • 114. Harvard University
  • 115. HH&E Ventures
  • 116. IBM
  • 117. Icagen
  • 118. Innovate UK
  • 119. Innovative Informatica Technologies
  • 120. Inserm
  • 121. Insilico Medicine
  • 122. Inte:Ligand
  • 123. Invus
  • 124. IOTA Pharmaceuticals
  • 125. Janssen Pharmaceuticals
  • 126. Janus Henderson Investors
  • 127. JPT Peptide Technologies
  • 128. Jubilant Biosys
  • 129. Juno Capital
  • 130. KWS BioTest
  • 131. Laxai Life Sciences
  • 132. Lead Discovery Siena
  • 133. Lead Molecular Design
  • 134. LeadInvent Technologies
  • 135. Legend Capital
  • 136. Liatris Biosciences
  • 137. Life Chemicals
  • 138. Longbow Capital
  • 139. LU Innovation, Lund University
  • 140. Mascot Industries
  • 141. Massachusetts Institute of Technology
  • 142. Medicilon
  • 143. Medisyn Technologies
  • 144. Medit
  • 145. Menarini Group
  • 146. Merck
  • 147. Micar Innovation
  • 148. Michaelson Capital Partners
  • 149. MIG Fonds
  • 150. Mind the Byte
  • 151. Molcode
  • 152. Molecular Cornerstones
  • 153. Molecular Discovery
  • 154. Molecular Forecaster
  • 155. Molsoft
  • 156. Morphic Therapeutics
  • 157. MPI Research
  • 158. Nanosyn
  • 159. National Institutes of Health
  • 160. New England Discovery Partners
  • 161. NiKem Research
  • 162. Nimbus Therapeutics
  • 163. Nodthera
  • 164. Nostrum Biodiscovery
  • 165. NovaData Solutions
  • 166. NovaLead Pharma
  • 167. NovAliX
  • 168. NovaMechanics
  • 169. Novartis
  • 170. Novo Holdings
  • 171. Novo Informatics
  • 172. National Science Foundation
  • 173. NuChem Therapeutics
  • 174. Numerate
  • 175. Oncotest
  • 176. Ono Pharmaceutical
  • 177. OTAVAchemicals
  • 178. Oxford Bioscience Partners
  • 179. Paraza Pharma
  • 180. Pars Silico Bioinformatics Laboratory
  • 181. PathoQuest
  • 182. Peakdale Molecular
  • 183. Petra Pharma
  • 184. Pharma Inventor
  • 185. Pharmacelera
  • 186. Pharmaceutical Product Development
  • 187. Pharmaron
  • 188. Phoenix Equity Partners
  • 189. Porton Pharma Solutions
  • 190. Prestwick Chemical
  • 191. Princeton BioMolecular Research
  • 192. Profacgen
  • 193. Prosarix
  • 194. ProSciens
  • 195. ProtoQSAR
  • 196. Provid Pharmaceuticals
  • 197. ProXyChem
  • 198. Pyxis Discovery
  • 199. Qsol Services India
  • 200. Quantitative Medicine
  • 201. RASA Life Science Informatics
  • 202. Rebexsess Discovery Chemistry
  • 203. Redmile Group
  • 204. Redox Scientific
  • 205. Resource & Environmental Consultants
  • 206. Rosa
  • 207. Rosetta Design Group
  • 208. RTI International
  • 209. Sai Life Sciences
  • 210. Sandexis
  • 211. Sanofi
  • 212. SARomics Biostructures
  • 213. Schrödinger
  • 214. Scientific Analysis Laboratories
  • 215. SciLifeLab
  • 216. Selvita
  • 217. Shechter Computational Solutions
  • 218. Shire
  • 219. SilcsBio
  • 220. Simulations Plus
  • 221. SmiLe Incubator
  • 222. Spectris
  • 223. Startup Health
  • 224. Struengmann Family Office
  • 225. Sundia MediTech
  • 226. Sygnature Discovery
  • 227. Syngene
  • 228. Synsight
  • 229. Taros Chemicals
  • 230. TCG Lifesciences
  • 231. The Carlyle Group
  • 232. Leukemia and Lymphoma Society
  • 233. Tri-Institutional Therapeutics Discovery Institute
  • 234. True PharmaChem
  • 235. Uni-Innovation Group
  • 236. University College London
  • 237. Van Drie Research
  • 238. Victrix Computational and Medicinal Chemistry Consultancy
  • 239. Vipergen
  • 240. Virtua Drug
  • 241. Viva Biotech
  • 242. VLife Sciences Technologies
  • 243. VLS 3D
  • 244. Wellcome Trust
  • 245. WIL Research Laboratories
  • 246. Wildcard Pharmaceutical Consulting
  • 247. Wilmington PharmaTech
  • 248. WuXi AppTec
  • 249. Wyss Institute
  • 250. XRQTC
  • 251. XtalPi
  • 252. ZoBio
  • 253. Zorilla Research
Back to Top